- Short name
- CaRAvAN
- Condition
- ANCA-associated vasculitis (AAV)
- Status
- Ongoing
- Study group
- Led by CanVasc members
Observational real-world study using data from the CanVasc registry to describe the characteristics and outcomes in AAV patients treated with avacopan in Canada. This study is partially supported by Canada’s Drug Agency (CDA) Rare Diseases Registry Funding and Otsuka Canada Pharmaceutical Inc.